secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001493152-24-031146
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona reports Q2 net income of $7.4M; FDA aligned on pz-cel BLA resubmission for 2H 2024
--------------------------------------------------------------------------------

- Net income of $7.4M in Q2 2024 (includes $24.9M gain on warrant liabilities) vs net loss of $16.7M in Q2 2023.
- Cash, cash equivalents, short-term investments and restricted cash total $123.0M as of June 30, 2024.
- Completed Type A meeting with FDA; preliminary alignment on CMC items; BLA resubmission for pz-cel on track for 2H 2024.
- Upon BLA acceptance, FDA expected to set PDUFA action date six months from submission date.
- Closed $75M underwritten securities offering in May 2024; $50M credit facility available; cash runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315224031146/0001493152-24-031146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315224031146/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer